FeesSafety
Pluang+

Class action lawsuit filed against Anavex Life Sciences over CEO firing and financial control issues.

Market News
14 Oct 2026, 00:24 WIB
GlobeNewsWire
View Source
Bearish
Class action lawsuit filed against Anavex Life Sciences over CEO firing and financial control issues.

Pomerantz LLP has filed a class action lawsuit against Anavex Life Sciences Corp. following the abrupt firing of its CEO for cause and the company's disclosure of a material weakness in financial controls. The CEO's termination announcement caused a 6.59% drop in Anavex's stock price, and the later admission of internal control issues led to another 6.35% decline. Investors who purchased Anavex securities during the class period have until November 30, 2026, to join the lawsuit or seek lead plaintiff status. This legal action highlights concerns about possible securities fraud and corporate mismanagement at Anavex.

Anavex Life Sciences Corp. is the subject of a class action lawsuit reminder amid recent corporate turmoil. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:41 WIB: out of 128 priced US health stocks, 29 rose and 99 fell. Notable movers include TXG at USD 71.79 with a 4.52% decline and 100% buy order activity, ERAS at USD 14.78 down 4.40% with 100% sell order activity, and NBIX at USD 135.50 down 4.15% with a nearly even buy/sell split.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
1 hour ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
1 hour ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
1 hour ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
3 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App